Nanōmix is the leader in the development of mobile, affordable point-of-care diagnostics. We offer a handheld testing platform and assays that provide rapid, accurate, quantitative information for use in settings where time-to-diagnosis is critical for clinical decision-making and improved patient care.

Our goal is to expand access to quality healthcare by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote, or alternative settings.

We have tests available or under development to aid in the diagnosis of sepsis, acute kidney injury, and SARS-CoV-2. Results are returned in just 10 minutes.

VIDEO INTRO READ MORE

The NANŌMIX eLab® System

FAST AND FULLY AUTOMATED POINT-OF-CARE DIAGNOSTIC SYSTEM

Results in minutes,
not hours or days.

Performance equal to a central laboratory system in a handheld, mobile device.

NEWS

29May2020

Five COVID-19 Test Developers to Watch (LINK)

Nanōmix is highlighted among the companies that could help provide the millions of COVID-19 tests that are needed to support safe re-opening.

testing for covid-19

POC testing

Point-of-Care Detection for Critical Infections

The Nanōmix S1 Assay detects and quantifies three key markers in blood to aid in the rapid detection of serious infections, including sepsis and bacteremia. The assay received CE Mark in December 2019 and is currently undergoing review by the U.S. FDA. Read more

Nanōmix eLab® System - Diagnostic Information in Minutes